Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taxus brings Boston $42million from first 10 days on US market

This article was originally published in Clinica

Executive Summary

Boston Scientific has reported US sales of its Taxus Express2 drug-eluting stent of $42m for the first 10 selling days after its launch. With the number of accounts the company is selling to ramping up rapidly, US Taxus revenues look like they will comfortably meet Boston's expectation of $52-75m for the 23 selling days to March 31.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT057710

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel